50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,696.80 (+1.36%)
DOW   29,526.29 (+1.34%)
QQQ   278.53 (+1.48%)
AAPL   147.37 (-2.89%)
MSFT   240.42 (+1.70%)
META   140.26 (+4.36%)
GOOGL   99.83 (+2.39%)
AMZN   117.28 (+2.51%)
TSLA   283.85 (+0.32%)
NVDA   127.19 (+2.47%)
NIO   17.26 (+0.41%)
BABA   80.54 (+3.43%)
AMD   68.53 (+2.02%)
T   15.89 (+1.02%)
MU   50.73 (+0.30%)
CGC   3.00 (+4.90%)
F   12.13 (+1.85%)
GE   64.84 (+0.57%)
DIS   99.03 (+3.32%)
AMC   7.59 (+1.88%)
PYPL   89.09 (+3.90%)
PFE   44.54 (+1.02%)
NFLX   240.64 (+7.26%)
S&P 500   3,696.80 (+1.36%)
DOW   29,526.29 (+1.34%)
QQQ   278.53 (+1.48%)
AAPL   147.37 (-2.89%)
MSFT   240.42 (+1.70%)
META   140.26 (+4.36%)
GOOGL   99.83 (+2.39%)
AMZN   117.28 (+2.51%)
TSLA   283.85 (+0.32%)
NVDA   127.19 (+2.47%)
NIO   17.26 (+0.41%)
BABA   80.54 (+3.43%)
AMD   68.53 (+2.02%)
T   15.89 (+1.02%)
MU   50.73 (+0.30%)
CGC   3.00 (+4.90%)
F   12.13 (+1.85%)
GE   64.84 (+0.57%)
DIS   99.03 (+3.32%)
AMC   7.59 (+1.88%)
PYPL   89.09 (+3.90%)
PFE   44.54 (+1.02%)
NFLX   240.64 (+7.26%)
S&P 500   3,696.80 (+1.36%)
DOW   29,526.29 (+1.34%)
QQQ   278.53 (+1.48%)
AAPL   147.37 (-2.89%)
MSFT   240.42 (+1.70%)
META   140.26 (+4.36%)
GOOGL   99.83 (+2.39%)
AMZN   117.28 (+2.51%)
TSLA   283.85 (+0.32%)
NVDA   127.19 (+2.47%)
NIO   17.26 (+0.41%)
BABA   80.54 (+3.43%)
AMD   68.53 (+2.02%)
T   15.89 (+1.02%)
MU   50.73 (+0.30%)
CGC   3.00 (+4.90%)
F   12.13 (+1.85%)
GE   64.84 (+0.57%)
DIS   99.03 (+3.32%)
AMC   7.59 (+1.88%)
PYPL   89.09 (+3.90%)
PFE   44.54 (+1.02%)
NFLX   240.64 (+7.26%)
S&P 500   3,696.80 (+1.36%)
DOW   29,526.29 (+1.34%)
QQQ   278.53 (+1.48%)
AAPL   147.37 (-2.89%)
MSFT   240.42 (+1.70%)
META   140.26 (+4.36%)
GOOGL   99.83 (+2.39%)
AMZN   117.28 (+2.51%)
TSLA   283.85 (+0.32%)
NVDA   127.19 (+2.47%)
NIO   17.26 (+0.41%)
BABA   80.54 (+3.43%)
AMD   68.53 (+2.02%)
T   15.89 (+1.02%)
MU   50.73 (+0.30%)
CGC   3.00 (+4.90%)
F   12.13 (+1.85%)
GE   64.84 (+0.57%)
DIS   99.03 (+3.32%)
AMC   7.59 (+1.88%)
PYPL   89.09 (+3.90%)
PFE   44.54 (+1.02%)
NFLX   240.64 (+7.26%)
NYSE:RCUS

Arcus Biosciences - RCUS Stock Forecast, Price & News

$26.51
+0.62 (+2.39%)
(As of 09/28/2022 12:20 PM ET)
Add
Compare
Today's Range
$26.10
$26.97
50-Day Range
$23.23
$28.93
52-Week Range
$16.74
$49.10
Volume
4,290 shs
Average Volume
620,094 shs
Market Capitalization
$1.91 billion
P/E Ratio
37.34
Dividend Yield
N/A
Price Target
$47.13

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.6% Upside
$47.13 Price Target
Short Interest
Bearish
18.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Arcus Biosciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$333,152 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.13) to ($4.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

579th out of 1,071 stocks

Pharmaceutical Preparations Industry

270th out of 531 stocks

RCUS stock logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

Arcus Biosciences, Inc. (NYSE:RCUS) COO Sells $333,151.56 in Stock
Arcus Biosciences (NYSE:RCUS) Trading Up 6.3%
First Week of RCUS November 18th Options Trading
Arcus Biosciences (NYSE:RCUS) Stock Price Down 6.8%
Why Precision BioSciences Shares Are Surging Today
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Company Calendar

Last Earnings
8/03/2022
Today
9/28/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
366
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.13
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+77.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$52.83 million
Pretax Margin
17.02%

Debt

Sales & Book Value

Annual Sales
$382.88 million
Cash Flow
$0.95 per share
Book Value
$11.98 per share

Miscellaneous

Free Float
62,996,000
Market Cap
$1.91 billion
Optionable
Optionable
Beta
0.75

Key Executives

  • Dr. Terry J. Rosen Ph.D. (Age 62)
    Co-Founder, Chairman & CEO
    Comp: $932.12k
  • Dr. Juan Carlos Jaen Ph.D. (Age 64)
    Co-Founder, Pres & Director
    Comp: $838.2k
  • Mr. Robert C. Goeltz IIMr. Robert C. Goeltz II (Age 49)
    Principal Financial & Accounting Officer and CFO
    Comp: $613.2k
  • Ms. Jennifer A. Jarrett M.B.A.Ms. Jennifer A. Jarrett M.B.A. (Age 51)
    COO & Director
    Comp: $828.2k
  • Ms. Carolyn C. Tang J.D.Ms. Carolyn C. Tang J.D. (Age 43)
    Gen. Counsel & Corp. Sec.
    Comp: $603.2k
  • Dr. Stephen Young Ph.D. (Age 53)
    Sr. VP of Technology & Quantitative Biology
  • Dr. Jonathan Yingling Ph.D. (Age 53)
    Chief Scientific Officer
  • Ms. Katherine Bock
    VP of Investor Relations & Corp. Strategy
  • Holli Kolkey
    VP of Corp. Communications
  • Ms. Yvonne Gehring
    Sr. VP of HR & Operations













RCUS Stock - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2022?

7 brokers have issued 1-year price objectives for Arcus Biosciences' stock. Their RCUS share price forecasts range from $36.00 to $60.00. On average, they predict the company's stock price to reach $47.13 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2022?

Arcus Biosciences' stock was trading at $40.47 at the start of the year. Since then, RCUS shares have decreased by 36.0% and is now trading at $25.89.
View the best growth stocks for 2022 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Wednesday, August, 3rd. The company reported ($0.93) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.93). The business earned $26.76 million during the quarter, compared to analysts' expectations of $21 million. Arcus Biosciences had a trailing twelve-month return on equity of 9.12% and a net margin of 16.34%. During the same quarter in the prior year, the company earned ($1.09) EPS.

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (6.15%), FMR LLC (4.60%), Pictet Asset Management SA (2.65%), Goldman Sachs Group Inc. (1.35%), Northern Trust Corp (0.94%) and UBS Asset Management Americas Inc. (0.62%). Insiders that own company stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $25.89.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.87 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.71 on an earnings per share basis.

How many employees does Arcus Biosciences have?

The company employs 366 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.